- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00083343
Caspofungin for the Treatment of Non-blood Candida Infections (0991-045)
February 20, 2017 updated by: Merck Sharp & Dohme LLC
A Multicenter, Open, Noncomparative Study to Estimate the Safety, Tolerability, and Efficacy of Caspofungin Acetate in the Treatment of Adults With Invasive Candida Infections (Excluding Patients With Candidemia as the Sole Site of Infection)
Candida is the most common fungal pathogen identified in hospitalized patients.
This study will seek to enroll adult patients (18 years of age or older) with invasive Candida infections (involving deep tissues and organs).
The study will not enroll patients whose only site of Candida infection was the bloodstream.
Patients that fulfill all study entry criteria will receive a single daily dose of caspofungin.
Caspofungin, an intravenous echinocandin antifungal agent, is already approved for the treatment of invasive candidiasis.
The dosage strength and duration of caspofungin will be individualized for each patient based on disease, severity of disease and extent of infection.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
48
Phase
- Phase 2
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- All patients must have at least 1 positive culture for Candida species obtained from an otherwise sterile, non-blood body site within 96 hours of the study entry.
- The patient must also have clinical evidence of Candida infection (e.g., oral temperature >100 degrees Fahrenheit, signs of inflammation from infected site, systolic blood pressure <90) within 96 hours of study entry.
- The patient must be at least 18 years old, and if a woman of child bearing potential, must have a negative serum or urine pregnancy test sensitive to 25 IU HCG prior to enrollment.
Exclusion Criteria:
- Patients whose only site of Candida infection was the bloodstream.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NON_RANDOMIZED
- Interventional Model: SINGLE_GROUP
- Masking: NONE
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
Favorable overall response rate
|
Secondary Outcome Measures
Outcome Measure |
---|
Favorable overall response rate on Day 10 of caspofungin therapy
|
Occurance of relapse during the 12 week follow-up period following the completion of all antifungal therapy
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
May 1, 2004
Primary Completion (ACTUAL)
February 1, 2006
Study Completion (ACTUAL)
February 1, 2006
Study Registration Dates
First Submitted
May 20, 2004
First Submitted That Met QC Criteria
May 21, 2004
First Posted (ESTIMATE)
May 24, 2004
Study Record Updates
Last Update Posted (ACTUAL)
February 23, 2017
Last Update Submitted That Met QC Criteria
February 20, 2017
Last Verified
February 1, 2017
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 0991-045
- Formerly-0404NBCI
- MK0991-045
- 2004_102
Plan for Individual participant data (IPD)
Study Data/Documents
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Candidiasis
-
Duke UniversityNational Institute of Allergy and Infectious Diseases (NIAID); Children's Hospital...CompletedPediatric Invasive CandidiasisUnited States, Colombia, Canada, India, Saudi Arabia, Greece, Italy, Spain
-
Robert Krause, MDCompletedInvasive Candidiasis | Pulmonary CandidiasisAustria
-
Centre Hospitalier Universitaire DijonCompleted
-
Astellas Pharma IncCompletedCandidemia | Invasive Candidiasis | Esophageal Candidiasis | Oropharyngeal CandidiasisUnited States, South Africa
-
Astellas Pharma IncCompletedCandidemia | Invasive Candidiasis | Esophageal Candidiasis | Oropharyngeal CandidiasisUnited States
-
Yung Shin Pharm. Ind. Co., Ltd.Completed
-
Duke UniversityChildren's Hospital of PhiladelphiaCompletedInvasive CandidiasisUnited States, Saudi Arabia, Greece, Spain
-
Merck Sharp & Dohme LLCTerminated
-
Hasan Al-DorziKing Fahad Medical CityCompleted
-
PfizerVicuron PharmaceuticalsCompleted
Clinical Trials on MK0991, caspofungin acetate/Duration of Treatment: variable
-
Merck Sharp & Dohme LLCCompleted
-
Merck Sharp & Dohme LLCCompleted
-
Merck Sharp & Dohme LLCCompleted
-
Merck Sharp & Dohme LLCCompleted
-
Merck Sharp & Dohme LLCCompletedCandidiasis | Aspergillosis
-
Merck Sharp & Dohme LLCCompleted
-
Merck Sharp & Dohme LLCCompleted
-
Merck Sharp & Dohme LLCCompleted
-
National Cancer Institute (NCI)CompletedSarcoma | Lymphoma | Kidney Cancer | Leukemia | Neutropenia | Neuroblastoma | Infection | Fever, Sweats, and Hot FlashesUnited States
-
European Organisation for Research and Treatment...CompletedMyelodysplastic Syndromes | Leukemia | Fungal InfectionBelgium, Netherlands, Germany, France, Czechia, Slovakia